Meropenem Steriscience (Meropenem Trihydrate)

Meropenem, the active ingredient in Meropenem Steriscience, is a carbapenem antibiotic presented as a sterile powder for intravenous use. It is employed to treat serious Gram‑negative and Gram‑positive bacterial infections in hospitalized adults and children.

GNH USA supplies Meropenem Steriscience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide, with rigorous quality assurance and regulatory compliance, ensuring consistent product integrity across all shipments.

Meropenem is a carbapenem antibiotic used for severe bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: provides effective treatment of resistant Gram‑negative uropathogens. - Bacterial meningitis: penetrates the cerebrospinal fluid to eradicate causative organisms. - Severe pneumonia: offers broad‑spectrum coverage against typical and atypical pathogens. - Sepsis: delivers rapid bactericidal activity in systemic infections.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: occasional feeling of queasiness. - Rash: transient skin erythema. - Elevated liver enzymes: mild transaminase increase. - Headache: occasional mild headache. - Injection site pain: discomfort at the IV site. - Fever: low‑grade temperature rise.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: antibiotic‑associated diarrhea. - Thrombocytopenia: low platelet count. - Renal dysfunction: acute kidney injury. - Hypotension: sudden drop in blood pressure.

When using Meropenem, clinicians should consider several precautionary measures to ensure safe therapy. - Renal function: adjust dose in patients with impaired renal function. - Hepatic function: monitor liver enzymes during prolonged therapy. - Seizure risk: avoid in patients with a history of seizures or CNS disorders. - Antibiotic stewardship: limit use to confirmed or strongly suspected bacterial infections to reduce resistance. - Drug hypersensitivity: assess for β‑lactam allergy before administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may reduce serum valproate levels, risking seizure breakthrough. - Probenecid: can increase meropenem concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: concurrent use may increase nephrotoxicity; monitor renal function. - Loop diuretics: may enhance ototoxic potential when combined with other ototoxic agents. - Anticoagulants: may potentiate bleeding; check coagulation parameters. - Oral contraceptives: possible reduction in effectiveness; advise alternative contraception. - Cefepime: additive neurotoxicity risk; monitor neurological status. - Immunosuppressants: may increase infection risk; observe for opportunistic infections.